CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) will be presenting today at the AABB
Symposium on Implementation of Pathogen-Reduced Blood Components taking
place in Bethesda, Maryland from April 27 to 28, 2015.
Cerus’ presentation will address the INTERCEPT Blood System today and
its future outlook, including:
-
Current FDA approved label claims for INTERCEPT, including the ability
to reduce transfusion-transmitted infectious risk in apheresis
platelet components, and apheresis or whole blood derived plasma
components.
-
Key potential blood center operational advantages, such as improved
platelet availability and reduced component wastage through early
platelet release with pathogen reduction.
-
Plans to expand claims to include a seven-day platelet shelf-life
extension, the ability to pathogen reduce whole blood derived
platelets, and the development of an INTERCEPT triple set storage kit
for improved platelet collection efficiency.
-
INTERCEPT red cell system developments, including the successful
completion of US Phase II and European Phase III trials.
Cerus’ presentation is part of AABB’s overall symposium agenda that will
cover considerations on the successful implementation of pathogen
reduction for blood collectors and transfusion services. The symposium
is being held in light of the recent FDA approvals, as well as a New
England Journal of Medicine article released last week in which US key
opinion leaders argue for an FDA mandate for pathogen reduction to
mitigate residual risks due to bacterial contamination, as well as
established and emerging transfusion-transmitted infections.1
In addition to US status and outlook, other presenters during the AABB
symposium will cover the extensive European experience with pathogen
reduction, including the implementation of INTERCEPT in Switzerland,
which involved the installation and validation of the system in 13 blood
transfusion centers within 11 months.
For further information about the symposium, visit:
http://www.aabb.org/development/Pages/pathogen-reduction-symposium.aspx.
1. Snyder EL, Stramer SL, Benjamin RJ. N Engl J Med. 2015 Apr 22, Epub
ahead of print.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood safety. The INTERCEPT Blood System is designed to reduce the
risk of transfusion-transmitted infections by inactivating a broad range
of pathogens such as viruses, bacteria and parasites that may be present
in donated blood. The nucleic acid targeting mechanism of action of the
INTERCEPT treatment is designed to inactivate established transfusion
threats, such as hepatitis B and C, HIV, West Nile virus and bacteria,
as well as emerging pathogens such as Chikungunya, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in the United States, Europe, the Commonwealth of
Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
This press release contains forward-looking statements. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements,
including, without limitation, statements relating to operational
advantages and ability to improve the timing of release for platelet
products; the uncertain and time-consuming development and
regulatory process, including risks related to Cerus‘ ability to expand
the label claims for THE INTERCEPT platelet systems in the U.S. and potential
expanded label claims for the INTERCEPT platelet systems in the U.S..
These forward-looking statements are based upon Cerus’ current
expectations. Actual results could differ materially from these
forward-looking statements as a result of certain factors, including,
without limitation, risks associated with the uncertainty of future
clinical trial results, the uncertain and time-consuming
regulatory process; and other risks detailed in Cerus' filings with the
SEC, including Cerus' annual report on Form 10-K filed with the SEC on
March 16, 2015. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Cerus does not undertake any obligation to update any
forward-looking statements as a result of new information, future
events, changed assumptions or otherwise.
Source: Cerus Corporation